Select Page

MVA Members


Biotech Companies

Mendus is leveraging its unparalleled expertise in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors.

With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Mendus is publicly traded on the Nasdaq Stockholm.

For more info visit